Below you can find some tables and results. However, I think we should only use figure 1 and table 1 (End of Page) and revise accordingly for publishing a brief communication.

Brief communication

Brief Communications should be in principle around up to 1,500 words in length (main text). The paper should be organized in the following sections: Introduction, Methods, Results, and Discussion. A structured abstract up to 200 words in length is required; the abstract should follow the following structure: Aim, Methods, Results, Conclusion. The reference list should be selective, containing no more than 20 selected references. Up to 2 figures and 1 table can be included.

_________________________________

Hypothesis

When Erenumab shows now efficacy, Botox is also ineffective, and vice versa.

Selection

Question: Right now all patients are included no matter of the reason to discharge first medication. If we state below “(super)Non-responder” it makes more sense to include only patients that discharged the first medication because of inefficacy. (EB n= 23, BE n= 24). Other than that Selection was made as follows

  1. Patients, that recieved Botox first and then Erenuemab (BE)

    Total Patients:604 Patients received Erenumab between 10/2022 – 12/2024

    Prior Botox Treatment & Up to 2 Additional Prophylactics (excluding antibodies) → 51 Patients

    Exclusions: 1 patient diagnosed with New Daily Persistent Headache (NDPH) & received external Botox not following PREEMPT protocol 1 patient received Botox off-label 3 patients received external Botox 20 patients lacked KSK or anamnesis data

Final Study Population: 26 Patients

  1. Patients, that recieved Erenumab first and then Botox (EB)

    Total Patients:  604 Patients received Erenumab between 10/2022 – 12/2024

    Max. 3 Prophylactics before Erenumab (excluding antibodies) → 377 Patients Stopped Erenumab and transitioned to Botox → 33 Patients

    Exclusions: 3 patients had antibodies before Botox 1 patient received Botox without forehead treatment 4 patients lacked headache data

Final Study Population: 25 Patients

Monthly headache days

MHD percentage of Change

Botox dann auch abgesetzt: EB 01 (Eff) EB 03 (Savety) EB 09 (Eff) EB 10 (Omit) EB 21 (Eff) EB 22 (Eff) nur einmal Botox erhalten EB 24 (Eff) Daten nicht auslesbar EB 26 (Eff) EB 27 (Savety) nur einmal BTX EB 32 (Eff) wg Darmerkrankung Erenu OMIT, BTX ohne wirkung EB 33 (Eff) nach 12 Monaten einen KSK Monat ansonsten nach einem Jahr abgesetzt

Grundlage für Table 1

overall NON-RESPONDER

NR = 0 (Change percent below 30%) NR = 1 (discharged) NR = 4 (Change of percent NA) -> only one because - no more visit

Botox Response NR = 3

Erenumab Response NR = 2

###non_responder_EB (code)

###non_responder_BE (code)

###Data_overall_NR (code)

###Data_overall_Ere_resp (code)

###Data_overall_Botox_resp (code)

Table 1 Data_combined

Table 1 provides a comparative summary of characteristics across three groups. The study population (n = 51) was filtered based on their only response to Botox (EB), to Erenumab (BE) or no response to both (NR). NNon-responders were filtered based on their reason for discontinuing the second medicatoin and/or their efficacy (less than 30% change in MHD).

It includes categorical variables presented as counts and percent (n (%)), continuous variables as means and standard deviations (Mean (SD)) and missing values where applicable.

Variable EB BE NR
n 5 7 39
Female (%) 4 (80.0) 7 (100.0) 33 (84.6)
Chronic Migraine (%) 5 (100.0) 7 (100.0) 39 (100.0)
Aura (%) 1 (20.0) 3 (42.9) 13 (33.3)
Smoking (%)
0 1 (20.0) 4 (57.1) 24 (61.5)
1 2 (40.0) 2 (28.6) 7 (17.9)
NA 2 (40.0) 1 (14.3) 8 (20.5)
Baseline Monthly Headache Days (mean (SD)) 19.00 (9.33) 22.14 (6.01) 19.26 (5.72)
Depression (%) 1 (20.0) 3 (42.9) 19 (48.7)
Anxiety (%) 2 (40.0) 1 (14.3) 8 (20.5)
Hypertension (%) 5 (100.0) 2 (28.6) 6 (15.4)
Medication-Overuse-Headache (%) 5 (100.0) 7 (100.0) 12 (30.8)
Age (mean (SD)) 35.58 (12.20) 51.42 (7.55) 40.00 (12.15)
Reason for Botox Discontinuation (Efficacy) 0 (0%) (5 NA) 7 (100%) (0 NA) 26 (66.7%) (48 NA)
Reason for Erenumab Discontinuation (Efficacy) 3 (60%) (0 NA) 0 (0%) (7 NA) 16 (41%) (48 NA)

DRAFT: Figure 1 Three Responder-Groups

  1. Selection Process TBD (s. comment in Selection)
  2. “Non-Responder” or “Super-Non-Responder”
  3. only drafted, but maybe show the shared pathway that is targeted by both CGRP-R mABs and BoNT.